PL2359809T3 - Formulacja o przedłużonym uwalnianiu zawierająca oktreotyd oraz dwa lub większą liczbę polimerów polilaktydo-ko-glikolidowych - Google Patents
Formulacja o przedłużonym uwalnianiu zawierająca oktreotyd oraz dwa lub większą liczbę polimerów polilaktydo-ko-glikolidowychInfo
- Publication number
- PL2359809T3 PL2359809T3 PL10175382T PL10175382T PL2359809T3 PL 2359809 T3 PL2359809 T3 PL 2359809T3 PL 10175382 T PL10175382 T PL 10175382T PL 10175382 T PL10175382 T PL 10175382T PL 2359809 T3 PL2359809 T3 PL 2359809T3
- Authority
- PL
- Poland
- Prior art keywords
- octreotide
- polylactide
- sustained release
- release formulation
- glycolide polymers
- Prior art date
Links
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title 1
- 108010016076 Octreotide Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960002700 octreotide Drugs 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyesters Or Polycarbonates (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0526247A GB0526247D0 (en) | 2005-12-22 | 2005-12-22 | Organic compounds |
| EP06119086 | 2006-08-17 | ||
| EP10175382.0A EP2359809B1 (en) | 2005-12-22 | 2006-12-20 | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
| PCT/EP2006/012313 WO2007071395A1 (en) | 2005-12-22 | 2006-12-20 | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
| EP06841059.6A EP1968549B1 (en) | 2005-12-22 | 2006-12-20 | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2359809T3 true PL2359809T3 (pl) | 2020-01-31 |
Family
ID=37772904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10175382T PL2359809T3 (pl) | 2005-12-22 | 2006-12-20 | Formulacja o przedłużonym uwalnianiu zawierająca oktreotyd oraz dwa lub większą liczbę polimerów polilaktydo-ko-glikolidowych |
| PL06841059T PL1968549T3 (pl) | 2005-12-22 | 2006-12-20 | Preparat o podtrzymywanym uwalnianiu zawierający okterotyd i dwa lub większą liczbę polimerów typu poli(mleczan-co-glikolan) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06841059T PL1968549T3 (pl) | 2005-12-22 | 2006-12-20 | Preparat o podtrzymywanym uwalnianiu zawierający okterotyd i dwa lub większą liczbę polimerów typu poli(mleczan-co-glikolan) |
Country Status (22)
| Country | Link |
|---|---|
| US (7) | US20090004283A1 (enExample) |
| EP (3) | EP1968549B1 (enExample) |
| JP (4) | JP2009520727A (enExample) |
| KR (5) | KR20140133968A (enExample) |
| CN (1) | CN103251929A (enExample) |
| AR (1) | AR058591A1 (enExample) |
| AU (1) | AU2006328950B2 (enExample) |
| BR (2) | BR122019027412B8 (enExample) |
| CA (1) | CA2631811C (enExample) |
| CL (1) | CL2018003398A1 (enExample) |
| EC (1) | ECSP088560A (enExample) |
| ES (2) | ES2492641T3 (enExample) |
| IL (1) | IL191842A0 (enExample) |
| IN (1) | IN2015DN03936A (enExample) |
| MA (1) | MA30064B1 (enExample) |
| NO (1) | NO20082988L (enExample) |
| PE (1) | PE20071139A1 (enExample) |
| PL (2) | PL2359809T3 (enExample) |
| PT (2) | PT2359809T (enExample) |
| RU (1) | RU2464972C2 (enExample) |
| TW (2) | TWI468172B (enExample) |
| WO (1) | WO2007071395A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2688478C (en) † | 2007-06-06 | 2015-10-27 | Debio Recherche Pharmaceutique S.A. | Slow release pharmaceutical composition made of microparticles |
| US8470360B2 (en) * | 2008-04-18 | 2013-06-25 | Warsaw Orthopedic, Inc. | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation |
| ES2324009B1 (es) * | 2007-11-23 | 2010-05-21 | Gp Pharm S.A. | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. |
| JP5791278B2 (ja) * | 2008-01-30 | 2015-10-07 | ノバルティス アーゲー | オクトレオチドおよび３種の線状ポリラクチド−コ−グリコリドポリマーを含む徐放性製剤 |
| AU2013201877B2 (en) * | 2008-01-30 | 2015-01-29 | Novartis Ag | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
| AU2015201581B2 (en) * | 2008-09-17 | 2017-03-09 | Amryt Endo, Inc. | Pharmaceutical Compositions and Related Methods of Delivery |
| HRP20170929T1 (hr) | 2008-09-17 | 2017-09-22 | Chiasma Inc. | Farmaceutski pripravci i odgovarajući postupci za isporuku |
| AR074603A1 (es) * | 2008-12-15 | 2011-01-26 | Novartis Ag | Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit |
| WO2010085609A2 (en) * | 2009-01-23 | 2010-07-29 | Surmodics Pharmaceuticals, Inc. | Controlled release systems from polymer blends |
| US20120022137A1 (en) * | 2010-07-21 | 2012-01-26 | Rivers Hongwen M | METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS |
| GB201016433D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Apparatus and method for making solid beads |
| GB201016436D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Method of making solid beads |
| US20120156304A1 (en) * | 2010-12-15 | 2012-06-21 | Thomas Tice | Branched polyol polyesters, blends, and pharmaceutical formulations comprising same |
| PL3199146T3 (pl) | 2011-04-25 | 2020-03-31 | Shan Dong Luye Pharmaceutical Co., Ltd. | Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu |
| CN102488619B (zh) * | 2011-12-05 | 2014-08-06 | 上海交通大学 | 连续生产艾塞那肽微球的装置及控制微球释放速度的方法 |
| JPWO2016084849A1 (ja) * | 2014-11-25 | 2017-10-12 | Cbc株式会社 | ヤヌス微粒子及びその製造方法 |
| AU2016215350B2 (en) | 2015-02-03 | 2021-11-25 | Amryt Endo, Inc. | Method of treating diseases |
| WO2016208685A1 (ja) * | 2015-06-26 | 2016-12-29 | オリンパス株式会社 | 内視鏡電源供給システム |
| US12396951B2 (en) * | 2016-12-27 | 2025-08-26 | Upexmed Co. Ltd. | Prevention of local tumor recurrence following surgery using sustainedand/or delayed release of medicaments contained in micro-particles |
| KR102142026B1 (ko) * | 2017-05-31 | 2020-08-06 | 주식회사 대웅제약 | 방출제어가 용이한 서방성 약물 미립자의 제조방법 |
| JP7704740B2 (ja) | 2019-09-16 | 2025-07-08 | アムジエン・インコーポレーテツド | 薬物送達デバイスの外部滅菌の方法 |
| CN111214643A (zh) * | 2020-03-11 | 2020-06-02 | 苏州善湾生物医药科技有限公司 | 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用 |
| JP6810502B1 (ja) * | 2020-05-08 | 2021-01-06 | エム・テクニック株式会社 | 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
| JP6852943B1 (ja) * | 2020-05-08 | 2021-03-31 | エム・テクニック株式会社 | 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤 |
| US20210346296A1 (en) * | 2020-05-08 | 2021-11-11 | M. Technique Co., Ltd. | A biologically active substance uniformly dispersed microsphere and a sustained release formulation comprising the same |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CY1327A (en) * | 1979-11-27 | 1986-06-27 | Sandoz Ag | Novel polypeptides,processes for their production,pharmaceutical compositions comprising said polypeptides and their use |
| US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| US5470582A (en) * | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| KR100260632B1 (ko) * | 1992-12-28 | 2000-07-01 | 성재갑 | 이식형 소마토트로핀 조성물 |
| US5603960A (en) * | 1993-05-25 | 1997-02-18 | O'hagan; Derek T. | Preparation of microparticles and method of immunization |
| US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US6447796B1 (en) * | 1994-05-16 | 2002-09-10 | The United States Of America As Represented By The Secretary Of The Army | Sustained release hydrophobic bioactive PLGA microspheres |
| DK0946169T3 (da) * | 1996-12-20 | 2003-04-22 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse |
| TW577759B (en) * | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
| ATE316779T1 (de) * | 1997-06-04 | 2006-02-15 | Debio Rech Pharma Sa | Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung |
| ES2169980B1 (es) * | 1999-12-17 | 2003-11-01 | Lipotec Sa | Microcapsulas para la liberacion prolongada de farmacos. |
| KR100392501B1 (ko) * | 2000-06-28 | 2003-07-22 | 동국제약 주식회사 | 다중 에멀젼법에 의한 서방출성 미립구의 제조방법 |
| EP1344520B1 (en) * | 2002-03-15 | 2007-10-03 | Alrise Biosystems GmbH | Microparticles and method for their production |
| BR0315304A (pt) * | 2002-11-06 | 2005-08-16 | Alza Corp | Formulações com depósito para liberação controlada |
| US20040097419A1 (en) * | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
| KR100466637B1 (ko) * | 2003-06-26 | 2005-01-13 | 주식회사 펩트론 | 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법 |
| CA2819769C (en) * | 2003-07-18 | 2016-06-28 | Oakwood Laboratories, L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| BRPI0412211A (pt) * | 2003-07-23 | 2006-08-22 | Pr Pharmaceuticals Inc | composições de liberação controlada |
| MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| AU2005271242B9 (en) * | 2004-08-12 | 2012-04-12 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical compositions for controlled release delivery of biologically active compounds |
-
2006
- 2006-12-20 EP EP06841059.6A patent/EP1968549B1/en active Active
- 2006-12-20 PL PL10175382T patent/PL2359809T3/pl unknown
- 2006-12-20 PE PE2006001665A patent/PE20071139A1/es not_active Application Discontinuation
- 2006-12-20 IN IN3936DEN2015 patent/IN2015DN03936A/en unknown
- 2006-12-20 PT PT101753820T patent/PT2359809T/pt unknown
- 2006-12-20 CA CA2631811A patent/CA2631811C/en active Active
- 2006-12-20 KR KR1020147031146A patent/KR20140133968A/ko not_active Ceased
- 2006-12-20 AR ARP060105668A patent/AR058591A1/es unknown
- 2006-12-20 AU AU2006328950A patent/AU2006328950B2/en active Active
- 2006-12-20 RU RU2008129626/15A patent/RU2464972C2/ru active
- 2006-12-20 PL PL06841059T patent/PL1968549T3/pl unknown
- 2006-12-20 BR BR122019027412A patent/BR122019027412B8/pt active IP Right Grant
- 2006-12-20 KR KR1020137004517A patent/KR101458728B1/ko active Active
- 2006-12-20 ES ES06841059.6T patent/ES2492641T3/es active Active
- 2006-12-20 BR BRPI0620063A patent/BRPI0620063B8/pt active IP Right Grant
- 2006-12-20 KR KR1020137004520A patent/KR20130024988A/ko not_active Ceased
- 2006-12-20 KR KR1020137004518A patent/KR20130024987A/ko not_active Ceased
- 2006-12-20 US US12/158,345 patent/US20090004283A1/en not_active Abandoned
- 2006-12-20 ES ES10175382T patent/ES2755032T3/es active Active
- 2006-12-20 WO PCT/EP2006/012313 patent/WO2007071395A1/en not_active Ceased
- 2006-12-20 PT PT68410596T patent/PT1968549E/pt unknown
- 2006-12-20 CN CN2013101523825A patent/CN103251929A/zh active Pending
- 2006-12-20 JP JP2008546248A patent/JP2009520727A/ja active Pending
- 2006-12-20 EP EP19188892.4A patent/EP3603623A1/en not_active Withdrawn
- 2006-12-20 EP EP10175382.0A patent/EP2359809B1/en active Active
- 2006-12-20 KR KR1020087014985A patent/KR101245919B1/ko active Active
- 2006-12-21 TW TW103107772A patent/TWI468172B/zh active
- 2006-12-21 TW TW95148218A patent/TWI469788B/zh active
-
2008
- 2008-05-29 IL IL191842A patent/IL191842A0/en unknown
- 2008-06-18 MA MA31048A patent/MA30064B1/fr unknown
- 2008-06-19 EC EC2008008560A patent/ECSP088560A/es unknown
- 2008-07-02 NO NO20082988A patent/NO20082988L/no not_active Application Discontinuation
-
2013
- 2013-04-25 JP JP2013092845A patent/JP6239851B2/ja active Active
-
2014
- 2014-10-08 JP JP2014207464A patent/JP6178772B2/ja active Active
- 2014-10-16 US US14/516,016 patent/US20150037420A1/en not_active Abandoned
-
2015
- 2015-12-22 US US14/977,801 patent/US20160120935A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115579A patent/JP2016216467A/ja not_active Withdrawn
-
2018
- 2018-01-17 US US15/873,473 patent/US20180140662A1/en not_active Abandoned
- 2018-11-29 CL CL2018003398A patent/CL2018003398A1/es unknown
-
2020
- 2020-03-10 US US16/813,864 patent/US20200206306A1/en not_active Abandoned
-
2022
- 2022-06-07 US US17/834,014 patent/US20220296675A1/en not_active Abandoned
-
2024
- 2024-11-22 US US18/956,119 patent/US20250082718A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL191842A0 (en) | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers | |
| HRP20130114T1 (xx) | Farmaceutski oblik s brzim oslobađanjem sinakalcet hci | |
| ZA200710270B (en) | Modified and immediate release memantine bead formulation | |
| IL190499A (en) | Formulation for delayed release of risperidone injectable | |
| IL209494A (en) | Formulations of insulin oligomeric monoconogues and their use | |
| ZA200705530B (en) | Sustained release pharmaceutical formulations | |
| IL214617A0 (en) | Use of controlled release formulations of octreotide | |
| GB0414825D0 (en) | Gel formulations and uses thereof | |
| IL188964A0 (en) | Sustained drug release composition | |
| IL178596A0 (en) | Sustained release formulations | |
| ZA200710858B (en) | Diclofenac formulations and methods of use | |
| EP1765385A4 (en) | IMPORTS COMPOSITION WITH DELAYED RELEASE | |
| IL213034A (en) | Stored formulations containing octrautide and two linear polylactide-line-glycolide polymers | |
| IL199168A0 (en) | Indolizine derivatives and the use thereof as antidiabetics | |
| EP1719794A4 (en) | ATYPICAL POLYMERS AND USES THEREOF | |
| PT2247282E (pt) | Formulação de libertação controlada compreendendo octreotido e três polímeros lineares de polilactido-coglicolido | |
| EP1802346A4 (en) | PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE | |
| IL181300A0 (en) | Photosensitizer formulations and uses thereof | |
| IL179497A0 (en) | Carboranylporphyrins and uses thereof | |
| GB0516069D0 (en) | Pharmaceutical and use thereof | |
| SI1863801T1 (sl) | Benzimidazolni derivat in njegova uporaba | |
| GB2434584B (en) | Solution composition and polymer light-emitting device | |
| ZA200705080B (en) | Aminocarboxylic acid derivative and medicinal use thereof | |
| PL2215908T3 (pl) | 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów | |
| IL180365A0 (en) | Carboranylporphyrins and uses thereof |